Fibrosarcoma: Clinical Trials

5 trials for Fibrosarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 terminated. 5 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Terminated 5
Phase 25Terminated 5

Follow Fibrosarcoma: new trials by email Literature Review of Fibrosarcoma trials Research Report on Fibrosarcoma

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
TNG908 - Locally Advanced Solid Tumor
Phase 1 / Phase 2TerminatedTango Therapeutics, Inc.1102022-03-232026-04-15
A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis
AL2846 capsules - Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors
Phase 1 / Phase 2TerminatedChia Tai Tianqing Pharmaceutical Group Co., Ltd.222021-09-072024-03-21
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)1512015-11-302022-08-23
PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
PLX3397, sirolimus - Sarcoma, Malignant Peripheral Nerve Sheath Tumors
Phase 1 / Phase 2TerminatedGulam Manji392015-11-042025-03-21
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination - Sarcoma, Leiomyosarcoma
Phase 1 / Phase 2TerminatedMemorial Sloan Kettering Cancer Center52011-08-012018-01-11

Narrower conditions

Neurofibrosarcoma (5)  ·  Sarcoma (3)  ·  Histiocytoma, Malignant Fibrous (2)  ·  Leiomyosarcoma (2)  ·  Cholangiocarcinoma (1)  ·  Dermatofibrosarcoma (1)  ·  Glioblastoma (1)  ·  Histiocytoma (1)  ·  Mesothelioma (1)  ·  Neurofibromatoses (1)  ·  Sarcoma, Synovial (1)

Broader conditions

Neoplasms (5)  ·  Neoplasms by Histologic Type (5)  ·  Neoplasms, Connective Tissue (5)  ·  Neoplasms, Connective and Soft Tissue (5)  ·  Neoplasms, Fibrous Tissue (5)  ·  Neoplasms, Nerve Tissue (5)  ·  Nerve Sheath Neoplasms (5)  ·  Nervous System Diseases (5)  ·  Nervous System Neoplasms (5)  ·  Neurofibroma (5)  ·  Neuromuscular Diseases (5)  ·  Peripheral Nervous System Diseases (5)  ·  Peripheral Nervous System Neoplasms (5)  ·  Neoplasms, Muscle Tissue (2)

Interventions

pazopanib (2)  ·  Docetaxel (1)  ·  Sirolimus (1)  ·  pexidartinib (1)  ·  sapanisertib (1)

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)  ·  Gulam Manji (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  National Cancer Institute (NCI) (1)  ·  Tango Therapeutics, Inc. (1)

Countries

United States (4)  ·  China (1)  ·  France (1)

Top investigators

Gulam A. Manji, MD (1)  ·  Maxim Pimkin, MD, PhD (1)  ·  William D Tap (1)  ·  William Tap, MD (1)

Results publications

PMID 34321280, PMID 39756156

NIH funding

U10CA180821 (1)